Clinical research on Qijiaoshengbai Capsules in treatment of leucopenia (deficiency of both qi and blood syndrome)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15006758

Enrollment

Unknown

Registered

2015-07-15

Start date

2015-07-30

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leucopenia (deficiency of both qi and blood syndrome)

Interventions

Treatment group:Qijiaoshengbai Capsules

Control group:Anduolin capsules

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Have all of the following 5 criteria: 1. Conform to the diagnosis of leucopenia and 2.0*10^9/L<WBC<4.0*10^9/L, or 0.5*10^9/L<NEUT#<2.0*10^9/L; 2. Age between 18~75 years old, not limited to gender; 3. In accordance with the standard of deficiency of qi and blood syndrome; 4. No serious diseases of heart, liver, kidney, blood and other systems; 5. Volunteers, and signed the informed consent.

Exclusion criteria

Exclusion criteria: Have any one of the following: 1. Not comply with the above inclusion criteria; 2. Leukopenia caused by infection or immune diseases; 3. Patients with hypersplenism, or patients with malignant tumor in radiotherapy or chemotherapy; 4. Pregnant or lactating women; 5. Mental patients; 6. Unable to follow the prescription in previous treatment.

Design outcomes

Primary

Measure	Time frame
WBC;NEUT;	—

Secondary

Measure	Time frame
TCM syndrome;	—

Countries

China

Contacts

Public ContactLi Hou

houli1203@126.com+86 13488695608

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026